Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 2/20 | 0.47 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 4/20 | 0.43 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.42 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.41 |
| ▸ | ACE | P12821 | 2/20 | 0.41 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16507899 | 0.95 | PTPN1 (0.44) | NPY4RRENACE | |
| SCHEMBL16507827 | 0.89 | ACE (0.49) | NPY4RRENF2KISS1RACE | |
| SCHEMBL16507942 | 0.85 | ACE (0.39) | NPY4RCRHR1CRHR2ACE | |
| SCHEMBL16358940 | 0.84 | ACE (0.38) | CRHR1CRHR2ACE | |
| SCHEMBL12045120 | 0.83 | REN (0.41) | RENKISS1RBACE1 | |
| SCHEMBL29790444 | 0.82 | NPY4R (0.48) | NPY4RKISS1R | |
| SCHEMBL31020877 | 0.82 | ACE (0.47) | NPY4RKISS1RACE | |
| SCHEMBL8894942 | 0.81 | GLP1R (0.53) | KISS1RCRHR1CRHR2IL23R | |
| SCHEMBL16508075 | 0.81 | NPY4R (0.53) | NPY4RKISS1RIL23R | |
| SCHEMBL30512722 | 0.81 | BACE1 (0.52) | F2BACE1CRHR1CRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | ANTHOR THERAPEUTICS, INC. | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | PTH1R, MC1R, CASR | NPY4R 1387/4885REN 525/4885F2 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.